Health care resource utilization (HCRU) and costs in patients with biliary tract cancer (BTC) treated with systemic therapy in the United States (US).

Authors

null

Liya Wang

Merck & Co., Inc., Kenilworth, NJ

Liya Wang , Mukul Singhal , Madhulika Eluri , Adriana Valderrama , Bal Nepal , Shital Kamble , Michael Grabner , Usha Malhotra , Abby B. Siegel , Shilpi Swami , Milind M. Javle

Organizations

Merck & Co., Inc., Kenilworth, NJ, HealthCore, Inc., Watertown, MA, MD Anderson Hematology/Oncology Fellowship, Houston, TX, HealthCore, Inc., Wilmington, DE, Merck Sharp & Dohme (UK) Limited, London, United Kingdom, University of Texas MD Anderson Cancer Center, Houston, TX

Research Funding

Pharmaceutical/Biotech Company

Background: BTC is associated with poor prognosis and limited treatment choices. There is limited evidence on HCRU and costs among BTC patients receiving systemic treatments (ST). This study examined HCRU and total direct cost of care among BTC patients treated with ST to understand the disease burden in management of BTC. Methods: A retrospective cohort study of BTC patients who received first line (1L) ST was conducted, using US private payer Cancer Care Quality Program data and administrative claims from the HealthCore Integrated Research Database between 07/01/2014 - 03/31/2021. Patients with ampullary cancer, brain/ CNS metastases, other primary cancer before BTC diagnosis were excluded. Per patient per month (PPPM) costs in 2020 USD were calculated during 1L, 2L, and 3L treatments associated with HCRU from inpatient, emergency room, and outpatient visits as well as outpatient pharmacy dispensing. Results: Among 298 BTC patients (biliary tract, n=203; gallbladder, n=65; bile duct, n=30; stage IV, n=231; stage III, n=28; stage I/II, n=39) who received ST, mean (SD) age was 61.7 (9) years at 1L treatment initiation, and the majority were female (58%). Following 1L treatment, 44% received 2L treatment, and 16% received 3L treatment. Median follow-up was 7.6 months. Among 201 (67%) patients who had hospitalization in the follow-up period, mean (SD) number of hospitalizations was 2.5 (2), and the average length of stay was 7.0 (5) days. Total PPPM all-cause costs were the lowest during 1L treatment (mean [SD]: $19,589 [$22,603]), and increased as the treatment advanced (2L: $22,617[$19,302]; 3L: $33,534[$40,588]). Similar trend was observed in BTC-related total costs with $16,237 ($22,452) in 1L, $19,083 ($18,670) in 2L and $27,609 ($39,949) in 3L. The table summarizes BTC-related HCRU and PPPM cost during each line of therapy. Conclusions: Study findings suggest significant resource use burden and high total direct medical costs for BTC patients receiving ST. Hospitalizations and outpatient visits represent important HCRU and cost for BTC. These data indicate a need for future newer innovative therapies in the management of BTC.

BTC-related HCRU and PPPM costs.

Description
During 1L Treatment
N=298
During 2L Treatment
N=132
During 3L Treatment
N=49
Duration of treatment, Mean (SD), months
3.8 (3.2)
4.1 (3.9)
4.6 (5.7)
Number of INP visits, mean (SD)
1.5 (0.9)
1.7 (1)
1.8 (1.2)
Number of ER visits, mean (SD)
1.1 (0.4)
1.3 (0.6)
1.4 (0.5)
Number of outpatient visits, mean (SD)
34.4 (31.7)
36.4 (37.1)
41.3 (34.7)
INP costs, mean (SD)
$7,630 ($20,889)
$6,678 ($13,738)
$13,601 ($39,094)
ER costs, mean (SD)
$247 ($921)
$158 ($534)
$240 ($949)
Outpatient visit costs, mean (SD)
$8,255 ($7,612)
$10,724 ($12,361)
$12,329 ($12,521)
Pharmacy costs, mean (SD)
$104 ($440)
$1,523 ($5,348)
$1,439 ($4,383)

Abbreviations: INP= Inpatient hospitalization; ER = Emergency room.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4090)

DOI

10.1200/JCO.2022.40.16_suppl.4090

Abstract #

4090

Poster Bd #

77

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.

First Author: Darren Cowzer

First Author: Preeti Kakani